ID   SCRIB_HUMAN             Reviewed;        1630 AA.
AC   Q14160; Q6P496; Q7Z5D1; Q8WWV8; Q96C69; Q96GG1;
DT   19-JUL-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-FEB-2022, sequence version 5.
DT   28-JUN-2023, entry version 222.
DE   RecName: Full=Protein scribble homolog;
DE            Short=Scribble;
DE            Short=hScrib;
DE   AltName: Full=Protein LAP4;
GN   Name=SCRIB; Synonyms=CRIB1, KIAA0147, LAP4, SCRB1, VARTUL;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), INTERACTION WITH LPP, SUBCELLULAR
RP   LOCATION, MUTAGENESIS OF 738-LEU--GLY-739; 872-LEU--GLY-873;
RP   1014-LEU--GLY-1015 AND 1111-LEU--GLY-1112, AND VARIANT LEU-422.
RX   PubMed=15649318; DOI=10.1186/1471-2121-6-1;
RA   Petit M.M.R., Meulemans S.M.P., Alen P., Ayoubi T.A.Y., Jansen E.,
RA   Van de Ven W.J.M.;
RT   "The tumor suppressor Scrib interacts with the zyxin-related protein LPP,
RT   which shuttles between cell adhesion sites and the nucleus.";
RL   BMC Cell Biol. 6:1-1(2005).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), VARIANT LEU-422, SUBCELLULAR
RP   LOCATION, MUTAGENESIS OF PRO-305, AND TISSUE SPECIFICITY.
RX   PubMed=15806148; DOI=10.1038/sj.onc.1208632;
RA   Navarro C., Nola S., Audebert S., Santoni M.-J., Arsanto J.-P.,
RA   Ginestier C., Marchetto S., Jacquemier J., Isnardon D., Le Bivic A.,
RA   Birnbaum D., Borg J.-P.;
RT   "Junctional recruitment of mammalian Scribble relies on E-cadherin
RT   engagement.";
RL   Oncogene 24:4330-4339(2005).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT LEU-422.
RA   Petit M.M.R., Alen P., Meulemans S.M.P., Van de Wouwer E., Ayoubi T.A.Y.,
RA   Van de Ven W.J.M., Jansen E.;
RT   "The human Scrib N1 variant encoded by the SCRIB gene contains 13 leucine-
RT   rich repeats and 4 PDZ domains.";
RL   Submitted (JUL-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1), AND VARIANT LEU-422.
RC   TISSUE=Bone marrow, and Brain;
RX   PubMed=8590280; DOI=10.1093/dnares/2.4.167;
RA   Nagase T., Seki N., Tanaka A., Ishikawa K., Nomura N.;
RT   "Prediction of the coding sequences of unidentified human genes. IV. The
RT   coding sequences of 40 new genes (KIAA0121-KIAA0160) deduced by analysis of
RT   cDNA clones from human cell line KG-1.";
RL   DNA Res. 2:167-174(1995).
RN   [5]
RP   SEQUENCE REVISION.
RX   PubMed=12168954; DOI=10.1093/dnares/9.3.99;
RA   Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.;
RT   "Construction of expression-ready cDNA clones for KIAA genes: manual
RT   curation of 330 KIAA cDNA clones.";
RL   DNA Res. 9:99-106(2002).
RN   [6]
RP   SEQUENCE REVISION.
RA   Ohara O., Nagase T., Kikuno R., Nomura N.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16421571; DOI=10.1038/nature04406;
RA   Nusbaum C., Mikkelsen T.S., Zody M.C., Asakawa S., Taudien S., Garber M.,
RA   Kodira C.D., Schueler M.G., Shimizu A., Whittaker C.A., Chang J.L.,
RA   Cuomo C.A., Dewar K., FitzGerald M.G., Yang X., Allen N.R., Anderson S.,
RA   Asakawa T., Blechschmidt K., Bloom T., Borowsky M.L., Butler J., Cook A.,
RA   Corum B., DeArellano K., DeCaprio D., Dooley K.T., Dorris L. III,
RA   Engels R., Gloeckner G., Hafez N., Hagopian D.S., Hall J.L., Ishikawa S.K.,
RA   Jaffe D.B., Kamat A., Kudoh J., Lehmann R., Lokitsang T., Macdonald P.,
RA   Major J.E., Matthews C.D., Mauceli E., Menzel U., Mihalev A.H.,
RA   Minoshima S., Murayama Y., Naylor J.W., Nicol R., Nguyen C., O'Leary S.B.,
RA   O'Neill K., Parker S.C.J., Polley A., Raymond C.K., Reichwald K.,
RA   Rodriguez J., Sasaki T., Schilhabel M., Siddiqui R., Smith C.L.,
RA   Sneddon T.P., Talamas J.A., Tenzin P., Topham K., Venkataraman V., Wen G.,
RA   Yamazaki S., Young S.K., Zeng Q., Zimmer A.R., Rosenthal A., Birren B.W.,
RA   Platzer M., Shimizu N., Lander E.S.;
RT   "DNA sequence and analysis of human chromosome 8.";
RL   Nature 439:331-335(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 799-1630 (ISOFORM 1), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1206-1630 (ISOFORM 3).
RC   TISSUE=Lung carcinoma, and Neuroblastoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   INTERACTION WITH UBE3A AND HPV E6, UBIQUITINATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=11027293; DOI=10.1128/mcb.20.21.8244-8253.2000;
RA   Nakagawa S., Huibregtse J.M.;
RT   "Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by
RT   the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein
RT   ligase.";
RL   Mol. Cell. Biol. 20:8244-8253(2000).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1220, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=15144186; DOI=10.1021/ac035352d;
RA   Brill L.M., Salomon A.R., Ficarro S.B., Mukherji M., Stettler-Gill M.,
RA   Peters E.C.;
RT   "Robust phosphoproteomic profiling of tyrosine phosphorylation sites from
RT   human T cells using immobilized metal affinity chromatography and tandem
RT   mass spectrometry.";
RL   Anal. Chem. 76:2763-2772(2004).
RN   [11]
RP   FUNCTION, INTERACTION WITH ARHGEF7 AND GIT1, SUBCELLULAR LOCATION, AND
RP   MUTAGENESIS OF PRO-305.
RX   PubMed=15182672; DOI=10.1016/j.cub.2004.05.051;
RA   Audebert S., Navarro C., Nourry C., Chasserot-Golaz S., Lecine P.,
RA   Bellaiche Y., Dupont J.-L., Premont R.T., Sempere C., Strub J.-M.,
RA   Van Dorsselaer A., Vitale N., Borg J.-P.;
RT   "Mammalian Scribble forms a tight complex with the betaPIX exchange
RT   factor.";
RL   Curr. Biol. 14:987-995(2004).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH TSHR.
RX   PubMed=15775968; DOI=10.1038/sj.emboj.7600616;
RA   Lahuna O., Quellari M., Achard C., Nola S., Meduri G., Navarro C.,
RA   Vitale N., Borg J.-P., Misrahi M.;
RT   "Thyrotropin receptor trafficking relies on the hScrib-betaPIX-GIT1-ARF6
RT   pathway.";
RL   EMBO J. 24:1364-1374(2005).
RN   [13]
RP   INTERACTION WITH TJP2.
RX   PubMed=15975580; DOI=10.1016/j.febslet.2005.05.062;
RA   Metais J.-Y., Navarro C., Santoni M.-J., Audebert S., Borg J.-P.;
RT   "hScrib interacts with ZO-2 at the cell-cell junctions of epithelial
RT   cells.";
RL   FEBS Lett. 579:3725-3730(2005).
RN   [14]
RP   INTERACTION WITH TRIP6.
RX   PubMed=16137684; DOI=10.1016/j.febslet.2005.08.012;
RA   Petit M.M.R., Crombez K.R.M.O., Vervenne H.B.V.K., Weyns N.,
RA   Van de Ven W.J.M.;
RT   "The tumor suppressor Scrib selectively interacts with specific members of
RT   the zyxin family of proteins.";
RL   FEBS Lett. 579:5061-5068(2005).
RN   [15]
RP   FUNCTION IN CELL ADHESION.
RX   PubMed=16344308; DOI=10.1083/jcb.200506094;
RA   Qin Y., Capaldo C., Gumbiner B.M., Macara I.G.;
RT   "The mammalian Scribble polarity protein regulates epithelial cell adhesion
RT   and migration through E-cadherin.";
RL   J. Cell Biol. 171:1061-1071(2005).
RN   [16]
RP   FUNCTION IN CELL PROLIFERATION, AND SUBCELLULAR LOCATION.
RX   PubMed=16965391; DOI=10.1111/j.1349-7006.2006.00315.x;
RA   Nagasaka K., Nakagawa S., Yano T., Takizawa S., Matsumoto Y., Tsuruga T.,
RA   Nakagawa K., Minaguchi T., Oda K., Hiraike-Wada O., Ooishi H., Yasugi T.,
RA   Taketani Y.;
RT   "Human homolog of Drosophila tumor suppressor Scribble negatively regulates
RT   cell-cycle progression from G1 to S phase by localizing at the basolateral
RT   membrane in epithelial cells.";
RL   Cancer Sci. 97:1217-1225(2006).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-853; SER-1306; SER-1309 AND
RP   SER-1378, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [18]
RP   INTERACTION WITH APC, AND SUBCELLULAR LOCATION.
RX   PubMed=16611247; DOI=10.1111/j.1365-2443.2006.00954.x;
RA   Takizawa S., Nagasaka K., Nakagawa S., Yano T., Nakagawa K., Yasugi T.,
RA   Takeuchi T., Kanda T., Huibregtse J.M., Akiyama T., Taketani Y.;
RT   "Human scribble, a novel tumor suppressor identified as a target of high-
RT   risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous
RT   polyposis coli.";
RL   Genes Cells 11:453-464(2006).
RN   [19]
RP   FUNCTION IN APOPTOSIS, SUBCELLULAR LOCATION, AND MUTAGENESIS OF PRO-305.
RX   PubMed=19041750; DOI=10.1016/j.cell.2008.09.045;
RA   Zhan L., Rosenberg A., Bergami K.C., Yu M., Xuan Z., Jaffe A.B., Allred C.,
RA   Muthuswamy S.K.;
RT   "Deregulation of scribble promotes mammary tumorigenesis and reveals a role
RT   for cell polarity in carcinoma.";
RL   Cell 135:865-878(2008).
RN   [20]
RP   FUNCTION IN CELL MIGRATION, AND INTERACTION WITH PAK1 AND PAK2.
RX   PubMed=18716323; DOI=10.1093/hmg/ddn248;
RA   Nola S., Sebbagh M., Marchetto S., Osmani N., Nourry C., Audebert S.,
RA   Navarro C., Rachel R., Montcouquiol M., Sans N., Etienne-Manneville S.,
RA   Borg J.-P., Santoni M.-J.;
RT   "Scrib regulates PAK activity during the cell migration process.";
RL   Hum. Mol. Genet. 17:3552-3565(2008).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1475 AND SER-1566, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [22]
RP   FUNCTION.
RX   PubMed=18641685; DOI=10.1038/onc.2008.219;
RA   Dow L.E., Elsum I.A., King C.L., Kinross K.M., Richardson H.E.,
RA   Humbert P.O.;
RT   "Loss of human Scribble cooperates with H-Ras to promote cell invasion
RT   through deregulation of MAPK signalling.";
RL   Oncogene 27:5988-6001(2008).
RN   [23]
RP   INTERACTION WITH TICK-BORNE ENCEPHALITIS VIRUS RNA-DIRECTED RNA POLYMERASE
RP   NS5.
RX   PubMed=18042258; DOI=10.1111/j.1462-5822.2007.01076.x;
RA   Werme K., Wigerius M., Johansson M.;
RT   "Tick-borne encephalitis virus NS5 associates with membrane protein
RT   scribble and impairs interferon-stimulated JAK-STAT signalling.";
RL   Cell. Microbiol. 10:696-712(2008).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-826; SER-939; SER-1223;
RP   SER-1232; SER-1306; SER-1309; THR-1342; SER-1348; SER-1437; SER-1547 AND
RP   SER-1566, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [26]
RP   INTERACTION WITH MCC.
RX   PubMed=19555689; DOI=10.1016/j.febslet.2009.06.034;
RA   Arnaud C., Sebbagh M., Nola S., Audebert S., Bidaut G., Hermant A.,
RA   Gayet O., Dusetti N.J., Ollendorff V., Santoni M.J., Borg J.P., Lecine P.;
RT   "MCC, a new interacting protein for Scrib, is required for cell migration
RT   in epithelial cells.";
RL   FEBS Lett. 583:2326-2332(2009).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1348 AND SER-1448, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-826; SER-1220; THR-1342;
RP   SER-1348; SER-1475; SER-1547 AND SER-1566, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [29]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-826; SER-835; SER-853;
RP   SER-939; SER-1140; SER-1220; SER-1232; THR-1342; SER-1348; SER-1378;
RP   SER-1448; SER-1475; SER-1486 AND SER-1566, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [30]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-688; THR-689; SER-1220;
RP   SER-1309 AND SER-1378, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [32]
RP   INTERACTION WITH MCC, AND SUBCELLULAR LOCATION.
RX   PubMed=22480440; DOI=10.1016/j.bbamcr.2012.03.011;
RA   Pangon L., Van Kralingen C., Abas M., Daly R.J., Musgrove E.A.,
RA   Kohonen-Corish M.R.;
RT   "The PDZ-binding motif of MCC is phosphorylated at position -1 and controls
RT   lamellipodia formation in colon epithelial cells.";
RL   Biochim. Biophys. Acta 1823:1058-1067(2012).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-37; THR-378; THR-475;
RP   SER-504; SER-708; SER-853; SER-875; SER-1140; SER-1220; SER-1223; SER-1226;
RP   SER-1232; SER-1276; SER-1279; SER-1306; SER-1309; SER-1348; SER-1378;
RP   SER-1448; SER-1475; SER-1486; SER-1508; SER-1541; SER-1561 AND SER-1566,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-504; SER-764; SER-853;
RP   SER-1140; SER-1220; SER-1295; SER-1298; SER-1306; SER-1309; SER-1378;
RP   SER-1445; SER-1448; SER-1486; SER-1508; THR-1545 AND SER-1566, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   FUNCTION, SUBCELLULAR LOCATION, PALMITOYLATION, AND MUTAGENESIS OF CYS-4;
RP   CYS-10; CYS-22 AND PRO-305.
RX   PubMed=27380321; DOI=10.1038/nchembio.2119;
RA   Chen B., Zheng B., DeRan M., Jarugumilli G.K., Fu J., Brooks Y.S., Wu X.;
RT   "ZDHHC7-mediated S-palmitoylation of Scribble regulates cell polarity.";
RL   Nat. Chem. Biol. 12:686-693(2016).
RN   [36]
RP   INTERACTION WITH DLG5; STK4 AND LATS1, AND SUBCELLULAR LOCATION.
RX   PubMed=28169360; DOI=10.1038/srep42125;
RA   Liu J., Li J., Li P., Wang Y., Liang Z., Jiang Y., Li J., Feng C., Wang R.,
RA   Chen H., Zhou C., Zhang J., Yang J., Liu P.;
RT   "Loss of DLG5 promotes breast cancer malignancy by inhibiting the Hippo
RT   signaling pathway.";
RL   Sci. Rep. 7:42125-42125(2017).
RN   [37]
RP   STRUCTURE BY NMR OF 718-814; 860-951 AND 1096-1193.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first, second and fourth PDZ domain of human
RT   scribble (KIAA0147 protein).";
RL   Submitted (NOV-2005) to the PDB data bank.
RN   [38]
RP   VARIANTS NTD SER-454 AND GLN-1535, AND CHARACTERIZATION OF VARIANTS NTD
RP   SER-454 AND GLN-1535.
RX   PubMed=22095531; DOI=10.1002/humu.21662;
RA   Robinson A., Escuin S., Doudney K., Vekemans M., Stevenson R.E.,
RA   Greene N.D., Copp A.J., Stanier P.;
RT   "Mutations in the planar cell polarity genes CELSR1 and SCRIB are
RT   associated with the severe neural tube defect craniorachischisis.";
RL   Hum. Mutat. 33:440-447(2012).
CC   -!- FUNCTION: Scaffold protein involved in different aspects of polarized
CC       cell differentiation regulating epithelial and neuronal morphogenesis
CC       and T-cell polarization (PubMed:15182672, PubMed:16344308,
CC       PubMed:19041750, PubMed:18716323, PubMed:18641685, PubMed:16965391,
CC       PubMed:27380321). Via its interaction with CRTAM, required for the late
CC       phase polarization of a subset of CD4+ T-cells, which in turn regulates
CC       TCR-mediated proliferation and IFNG and IL22 production (By
CC       similarity). Most probably functions in the establishment of apico-
CC       basal cell polarity (PubMed:16344308, PubMed:19041750). May function in
CC       cell proliferation regulating progression from G1 to S phase and as a
CC       positive regulator of apoptosis for instance during acinar
CC       morphogenesis of the mammary epithelium (PubMed:16965391,
CC       PubMed:19041750). May also function in cell migration and adhesion and
CC       hence regulate cell invasion through MAPK signaling (PubMed:18716323,
CC       PubMed:18641685). May play a role in exocytosis and in the targeting of
CC       synaptic vesicles to synapses (PubMed:15182672). Functions as an
CC       activator of Rac GTPase activity. {ECO:0000250|UniProtKB:Q80U72,
CC       ECO:0000269|PubMed:15182672, ECO:0000269|PubMed:16344308,
CC       ECO:0000269|PubMed:16965391, ECO:0000269|PubMed:18641685,
CC       ECO:0000269|PubMed:18716323, ECO:0000269|PubMed:19041750,
CC       ECO:0000269|PubMed:27380321}.
CC   -!- SUBUNIT: Interacts with UBE3A (PubMed:11027293). Interacts with PAK1
CC       and PAK2 (PubMed:18716323). Interacts (via PDZ domains) with VANGL2 (By
CC       similarity). Interacts (via PDZ domains) with LPP and TRIP6; the
CC       interaction is direct (PubMed:15649318, PubMed:16137684). Interacts
CC       (via PDZ domains) with TJP2 (PubMed:15975580). Interacts (via PDZ
CC       domains) with APC; may mediate APC targeting to adherens junctions of
CC       epithelial cells (PubMed:16611247). Interacts (via PDZ domains) with
CC       TSHR; regulates TSHR trafficking and function (PubMed:15775968).
CC       Interacts with ARHGEF7 and GIT1; interacts directly with ARHGEF7
CC       (PubMed:15182672). Interacts with CTNNB1 (By similarity). Interacts
CC       with MAPK12 (By similarity). Interacts (via PDZ domains 1 and 3) with
CC       MCC (PubMed:19555689, PubMed:22480440). Interacts with DLG5
CC       (PubMed:28169360). Interacts with STK4/MST1 and LATS1 in the presence
CC       of DLG5 (PubMed:28169360). Interacts (via PDZ domain 3) with CRTAM (via
CC       PDZ-binding motif); the interaction promotes CRTAM and SCRIB
CC       polarization in a subset of CD4+ T-cells (By similarity).
CC       {ECO:0000250|UniProtKB:Q80U72, ECO:0000269|PubMed:11027293,
CC       ECO:0000269|PubMed:15182672, ECO:0000269|PubMed:15649318,
CC       ECO:0000269|PubMed:15775968, ECO:0000269|PubMed:15975580,
CC       ECO:0000269|PubMed:16137684, ECO:0000269|PubMed:16611247,
CC       ECO:0000269|PubMed:18716323, ECO:0000269|PubMed:19555689,
CC       ECO:0000269|PubMed:22480440, ECO:0000269|PubMed:28169360}.
CC   -!- SUBUNIT: (Microbial infection) Interacts (via fourth PDZ domain) with
CC       tick-borne encephalitis virus RNA-directed RNA polymerase NS5; this
CC       interaction targets viral NS5 to the cell membrane periphery and
CC       nucleus and prevents STAT1 phosphorylation, and thus, the activation of
CC       the JAK-STAT signaling pathway (PubMed:18042258). Interacts with HPV E6
CC       (PubMed:11027293). {ECO:0000269|PubMed:11027293,
CC       ECO:0000269|PubMed:18042258}.
CC   -!- INTERACTION:
CC       Q14160; Q9P0K1: ADAM22; NbExp=3; IntAct=EBI-357345, EBI-1567236;
CC       Q14160; P25100: ADRA1D; NbExp=19; IntAct=EBI-357345, EBI-489993;
CC       Q14160; P25054: APC; NbExp=5; IntAct=EBI-357345, EBI-727707;
CC       Q14160; Q5VV41: ARHGEF16; NbExp=2; IntAct=EBI-357345, EBI-1057448;
CC       Q14160; Q14155: ARHGEF7; NbExp=11; IntAct=EBI-357345, EBI-717515;
CC       Q14160; P20020: ATP2B1; NbExp=2; IntAct=EBI-357345, EBI-5279998;
CC       Q14160; Q01814: ATP2B2; NbExp=2; IntAct=EBI-357345, EBI-1174243;
CC       Q14160; P34998: CRHR1; NbExp=3; IntAct=EBI-357345, EBI-3870393;
CC       Q14160; Q9UQB3: CTNND2; NbExp=2; IntAct=EBI-357345, EBI-7266482;
CC       Q14160; Q9NS75: CYSLTR2; NbExp=3; IntAct=EBI-357345, EBI-3843579;
CC       Q14160; O00429: DNM1L; NbExp=2; IntAct=EBI-357345, EBI-724571;
CC       Q14160; P0C2L3: FAM163B; NbExp=3; IntAct=EBI-357345, EBI-11793223;
CC       Q14160; Q7L8L6: FASTKD5; NbExp=2; IntAct=EBI-357345, EBI-747570;
CC       Q14160; Q14CM0: FRMPD4; NbExp=2; IntAct=EBI-357345, EBI-311279;
CC       Q14160; P33402: GUCY1A2; NbExp=6; IntAct=EBI-357345, EBI-6911715;
CC       Q14160; P22460: KCNA5; NbExp=2; IntAct=EBI-357345, EBI-6426121;
CC       Q14160; Q14500: KCNJ12; NbExp=2; IntAct=EBI-357345, EBI-11794596;
CC       Q14160; P63252: KCNJ2; NbExp=2; IntAct=EBI-357345, EBI-703457;
CC       Q14160; P48050: KCNJ4; NbExp=2; IntAct=EBI-357345, EBI-706117;
CC       Q14160; P53778: MAPK12; NbExp=6; IntAct=EBI-357345, EBI-602406;
CC       Q14160; P27361: MAPK3; NbExp=2; IntAct=EBI-357345, EBI-73995;
CC       Q14160; P23508: MCC; NbExp=14; IntAct=EBI-357345, EBI-307531;
CC       Q14160; Q7Z628: NET1; NbExp=2; IntAct=EBI-357345, EBI-2511306;
CC       Q14160; Q96DL1: NXPE2; NbExp=2; IntAct=EBI-357345, EBI-11791121;
CC       Q14160; O60346: PHLPP1; NbExp=2; IntAct=EBI-357345, EBI-2511516;
CC       Q14160; Q99569: PKP4; NbExp=4; IntAct=EBI-357345, EBI-726447;
CC       Q14160; Q15311: RALBP1; NbExp=2; IntAct=EBI-357345, EBI-749285;
CC       Q14160; Q15418: RPS6KA1; NbExp=3; IntAct=EBI-357345, EBI-963034;
CC       Q14160; Q15349: RPS6KA2; NbExp=9; IntAct=EBI-357345, EBI-1384149;
CC       Q14160; A6NIM6: SLC15A5; NbExp=2; IntAct=EBI-357345, EBI-11792220;
CC       Q14160; P48065: SLC6A12; NbExp=2; IntAct=EBI-357345, EBI-3843589;
CC       Q14160; Q9C0D5: TANC1; NbExp=4; IntAct=EBI-357345, EBI-11023211;
CC       Q14160; P16473: TSHR; NbExp=3; IntAct=EBI-357345, EBI-13939599;
CC       Q14160; Q14D04: VEPH1; NbExp=2; IntAct=EBI-357345, EBI-1043669;
CC       Q14160; A6NIX2: WTIP; NbExp=2; IntAct=EBI-357345, EBI-20730502;
CC       Q14160; Q9GZV5: WWTR1; NbExp=3; IntAct=EBI-357345, EBI-747743;
CC       Q14160; P46937: YAP1; NbExp=2; IntAct=EBI-357345, EBI-1044059;
CC       Q14160; B7Z2Y1; NbExp=3; IntAct=EBI-357345, EBI-11791049;
CC       Q14160; P03126: E6; Xeno; NbExp=8; IntAct=EBI-357345, EBI-1177242;
CC       Q14160; P06427: E6; Xeno; NbExp=3; IntAct=EBI-357345, EBI-11737184;
CC       Q14160; P06463: E6; Xeno; NbExp=4; IntAct=EBI-357345, EBI-1186926;
CC       Q14160; P24835: E6; Xeno; NbExp=2; IntAct=EBI-357345, EBI-11793707;
CC       Q14160; Q9QXA3: Fat1; Xeno; NbExp=5; IntAct=EBI-357345, EBI-6980218;
CC       Q14160; P0C213: tax; Xeno; NbExp=2; IntAct=EBI-357345, EBI-11793850;
CC       Q14160; P0C222: tax; Xeno; NbExp=2; IntAct=EBI-357345, EBI-11794384;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:28169360};
CC       Peripheral membrane protein. Cell junction
CC       {ECO:0000269|PubMed:27380321}. Cell junction, adherens junction. Cell
CC       projection, lamellipodium. Cytoplasm. Postsynapse
CC       {ECO:0000269|PubMed:15182672}. Presynapse
CC       {ECO:0000269|PubMed:15182672}. Note=Targeting to cell-cell junctions
CC       which is CDH1-dependent is required for the pro-apoptotic activity. In
CC       a subset of CD4+ T-cells, colocalizes with CRTAM at the immunological
CC       synapse during the late phase of T-cell activation (By similarity).
CC       {ECO:0000250|UniProtKB:Q80U72}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q14160-1; Sequence=Displayed;
CC       Name=2; Synonyms=Variant N1;
CC         IsoId=Q14160-2; Sequence=VSP_010906;
CC       Name=3;
CC         IsoId=Q14160-3; Sequence=VSP_010908;
CC   -!- TISSUE SPECIFICITY: Expressed in kidney, skeletal muscles, liver, lung,
CC       breast, intestine, placenta and skin mainly in epithelial cells (at
CC       protein level). {ECO:0000269|PubMed:15806148}.
CC   -!- PTM: Ubiquitinated; targeted for UBE3A-dependent multiubiquitination in
CC       the presence of high-risk HPV E6 proteins and degraded.
CC       {ECO:0000269|PubMed:11027293}.
CC   -!- PTM: Palmitoylated (PubMed:27380321). Could be depalmitoylated by
CC       LYPLA1 and/or LYPLA2 (PubMed:27380321). Palmitoylation of SCRIB by
CC       ZDHHC7 is required for its localization to cell-cell junctions,
CC       function in the establishement of epithelial cell polarity and the
CC       regulation of downstream signaling pathways important for epithelial
CC       cell differentiation (PubMed:27380321). {ECO:0000269|PubMed:27380321}.
CC   -!- DISEASE: Neural tube defects (NTD) [MIM:182940]: Congenital
CC       malformations of the central nervous system and adjacent structures
CC       related to defective neural tube closure during the first trimester of
CC       pregnancy. Failure of neural tube closure can occur at any level of the
CC       embryonic axis. Common NTD forms include anencephaly, myelomeningocele
CC       and spina bifida, which result from the failure of fusion in the
CC       cranial and spinal region of the neural tube. NTDs have a
CC       multifactorial etiology encompassing both genetic and environmental
CC       components. {ECO:0000269|PubMed:22095531}. Note=The disease is caused
CC       by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the LAP (LRR and PDZ) protein family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF240677; AAP88017.1; -; mRNA.
DR   EMBL; AY062238; AAL38976.1; -; mRNA.
DR   EMBL; AF271734; AAP88018.2; -; mRNA.
DR   EMBL; D63481; BAA09768.3; -; mRNA.
DR   EMBL; AC105219; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; KF458881; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC009490; AAH09490.2; -; mRNA.
DR   EMBL; BC014632; AAH14632.2; -; mRNA.
DR   CCDS; CCDS6411.1; -. [Q14160-1]
DR   CCDS; CCDS6412.1; -. [Q14160-3]
DR   RefSeq; NP_056171.3; NM_015356.4. [Q14160-1]
DR   RefSeq; NP_874365.3; NM_182706.4. [Q14160-3]
DR   PDB; 1UJU; NMR; -; A=1096-1193.
DR   PDB; 1WHA; NMR; -; A=860-951.
DR   PDB; 1X5Q; NMR; -; A=718-814.
DR   PDB; 2W4F; X-ray; 1.30 A; A=725-815.
DR   PDB; 4WYT; X-ray; 2.60 A; A=992-1203.
DR   PDB; 4WYU; X-ray; 2.50 A; A/B=992-1203.
DR   PDB; 5VWC; X-ray; 1.91 A; A=725-815.
DR   PDB; 5VWI; X-ray; 1.75 A; A/B=1002-1092.
DR   PDB; 5VWK; X-ray; 2.35 A; A/B/C/D=700-816.
DR   PDB; 6EEY; X-ray; 1.15 A; A=1098-1189.
DR   PDB; 6ESP; NMR; -; A=719-829.
DR   PDB; 6MS1; X-ray; 1.35 A; A/B=722-815.
DR   PDB; 6MTU; X-ray; 2.14 A; A/B=700-816.
DR   PDB; 6MTV; X-ray; 2.60 A; A/B=700-816.
DR   PDB; 6MYE; X-ray; 1.10 A; A=725-815.
DR   PDB; 6MYF; X-ray; 1.60 A; A=725-815.
DR   PDB; 6XA6; X-ray; 1.95 A; A/B=1002-1092.
DR   PDB; 6XA7; X-ray; 2.50 A; A/B/C/D=860-950.
DR   PDB; 6XA8; X-ray; 2.20 A; A/B=700-816.
DR   PDB; 7JO7; X-ray; 2.44 A; A/B/C/D=860-950.
DR   PDB; 7QRS; X-ray; 1.77 A; A/B=700-816.
DR   PDB; 7QRT; X-ray; 1.90 A; A/B=859-950.
DR   PDB; 7QS8; X-ray; 1.85 A; A/B=1002-1092.
DR   PDB; 7QS9; X-ray; 1.80 A; A/B=700-816.
DR   PDB; 7QSA; X-ray; 2.02 A; A/B=1002-1092.
DR   PDB; 7QSB; X-ray; 1.84 A; A/B=1002-1092.
DR   PDB; 7QTO; X-ray; 3.50 A; A/B=700-816.
DR   PDB; 7QTP; X-ray; 1.90 A; A=700-816.
DR   PDB; 7QTU; X-ray; 2.84 A; A/B/E/G=1002-1092.
DR   PDBsum; 1UJU; -.
DR   PDBsum; 1WHA; -.
DR   PDBsum; 1X5Q; -.
DR   PDBsum; 2W4F; -.
DR   PDBsum; 4WYT; -.
DR   PDBsum; 4WYU; -.
DR   PDBsum; 5VWC; -.
DR   PDBsum; 5VWI; -.
DR   PDBsum; 5VWK; -.
DR   PDBsum; 6EEY; -.
DR   PDBsum; 6ESP; -.
DR   PDBsum; 6MS1; -.
DR   PDBsum; 6MTU; -.
DR   PDBsum; 6MTV; -.
DR   PDBsum; 6MYE; -.
DR   PDBsum; 6MYF; -.
DR   PDBsum; 6XA6; -.
DR   PDBsum; 6XA7; -.
DR   PDBsum; 6XA8; -.
DR   PDBsum; 7JO7; -.
DR   PDBsum; 7QRS; -.
DR   PDBsum; 7QRT; -.
DR   PDBsum; 7QS8; -.
DR   PDBsum; 7QS9; -.
DR   PDBsum; 7QSA; -.
DR   PDBsum; 7QSB; -.
DR   PDBsum; 7QTO; -.
DR   PDBsum; 7QTP; -.
DR   PDBsum; 7QTU; -.
DR   AlphaFoldDB; Q14160; -.
DR   SMR; Q14160; -.
DR   BioGRID; 117060; 243.
DR   ComplexPortal; CPX-6168; Scribble cell polarity complex, DLG1-LLGL2-SCRIB variant.
DR   ComplexPortal; CPX-6184; Scribble cell polarity complex, DLG2-LLGL2-SCRIB variant.
DR   ComplexPortal; CPX-6185; Scribble cell polarity complex, DLG3-LLGL2-SCRIB variant.
DR   ComplexPortal; CPX-6186; Scribble cell polarity complex, DLG4-LLGL2-SCRIB variant.
DR   ComplexPortal; CPX-6187; Scribble cell polarity complex, DLG5-LLGL2-SCRIB variant.
DR   ComplexPortal; CPX-6188; Scribble cell polarity complex, DLG5-LLGL1-SCRIB variant.
DR   ComplexPortal; CPX-6189; Scribble cell polarity complex, DLG4-LLGL1-SCRIB variant.
DR   ComplexPortal; CPX-6190; Scribble cell polarity complex, DLG3-LLGL1-SCRIB variant.
DR   ComplexPortal; CPX-6191; Scribble cell polarity complex, DLG2-LLGL1-SCRIB variant.
DR   ComplexPortal; CPX-6192; Scribble cell polarity complex, DLG1-LLGL1-SCRIB variant.
DR   CORUM; Q14160; -.
DR   DIP; DIP-31259N; -.
DR   ELM; Q14160; -.
DR   IntAct; Q14160; 201.
DR   MINT; Q14160; -.
DR   STRING; 9606.ENSP00000349486; -.
DR   MoonDB; Q14160; Predicted.
DR   GlyCosmos; Q14160; 1 site, 2 glycans.
DR   GlyGen; Q14160; 3 sites, 2 O-linked glycans (3 sites).
DR   iPTMnet; Q14160; -.
DR   PhosphoSitePlus; Q14160; -.
DR   SwissPalm; Q14160; -.
DR   BioMuta; SCRIB; -.
DR   DMDM; 261260101; -.
DR   EPD; Q14160; -.
DR   jPOST; Q14160; -.
DR   MassIVE; Q14160; -.
DR   MaxQB; Q14160; -.
DR   PaxDb; Q14160; -.
DR   PeptideAtlas; Q14160; -.
DR   ProteomicsDB; 59873; -. [Q14160-1]
DR   ProteomicsDB; 59874; -. [Q14160-2]
DR   ProteomicsDB; 59875; -. [Q14160-3]
DR   Antibodypedia; 43533; 158 antibodies from 27 providers.
DR   DNASU; 23513; -.
DR   Ensembl; ENST00000320476.7; ENSP00000322938.3; ENSG00000180900.20. [Q14160-1]
DR   Ensembl; ENST00000356994.7; ENSP00000349486.2; ENSG00000180900.20. [Q14160-3]
DR   Ensembl; ENST00000377533.7; ENSP00000366756.3; ENSG00000180900.20. [Q14160-2]
DR   Ensembl; ENST00000611528.2; ENSP00000479898.1; ENSG00000274287.4. [Q14160-2]
DR   Ensembl; ENST00000612204.4; ENSP00000484041.1; ENSG00000274287.4. [Q14160-3]
DR   Ensembl; ENST00000622455.4; ENSP00000482406.1; ENSG00000274287.4. [Q14160-1]
DR   GeneID; 23513; -.
DR   KEGG; hsa:23513; -.
DR   MANE-Select; ENST00000356994.7; ENSP00000349486.2; NM_182706.5; NP_874365.3. [Q14160-3]
DR   UCSC; uc003yzo.1; human. [Q14160-1]
DR   AGR; HGNC:30377; -.
DR   CTD; 23513; -.
DR   DisGeNET; 23513; -.
DR   GeneCards; SCRIB; -.
DR   HGNC; HGNC:30377; SCRIB.
DR   HPA; ENSG00000180900; Tissue enhanced (esophagus).
DR   MalaCards; SCRIB; -.
DR   MIM; 182940; phenotype.
DR   MIM; 607733; gene.
DR   neXtProt; NX_Q14160; -.
DR   OpenTargets; ENSG00000180900; -.
DR   PharmGKB; PA134936275; -.
DR   VEuPathDB; HostDB:ENSG00000180900; -.
DR   eggNOG; KOG0619; Eukaryota.
DR   GeneTree; ENSGT00940000154025; -.
DR   HOGENOM; CLU_000288_18_20_1; -.
DR   InParanoid; Q14160; -.
DR   OrthoDB; 2909504at2759; -.
DR   PhylomeDB; Q14160; -.
DR   TreeFam; TF351429; -.
DR   PathwayCommons; Q14160; -.
DR   Reactome; R-HSA-4608870; Asymmetric localization of PCP proteins.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013406; RHOQ GTPase cycle.
DR   Reactome; R-HSA-9013409; RHOJ GTPase cycle.
DR   Reactome; R-HSA-9696264; RND3 GTPase cycle.
DR   Reactome; R-HSA-9696270; RND2 GTPase cycle.
DR   SignaLink; Q14160; -.
DR   SIGNOR; Q14160; -.
DR   BioGRID-ORCS; 23513; 34 hits in 1156 CRISPR screens.
DR   ChiTaRS; SCRIB; human.
DR   EvolutionaryTrace; Q14160; -.
DR   GeneWiki; SCRIB; -.
DR   GenomeRNAi; 23513; -.
DR   Pharos; Q14160; Tbio.
DR   PRO; PR:Q14160; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   RNAct; Q14160; protein.
DR   Bgee; ENSG00000180900; Expressed in lower esophagus mucosa and 91 other tissues.
DR   ExpressionAtlas; Q14160; baseline and differential.
DR   Genevisible; Q14160; HS.
DR   GO; GO:0005912; C:adherens junction; IDA:UniProtKB.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0044291; C:cell-cell contact zone; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0099147; C:extrinsic component of postsynaptic density membrane; IEA:Ensembl.
DR   GO; GO:0098978; C:glutamatergic synapse; IEA:Ensembl.
DR   GO; GO:0001772; C:immunological synapse; ISS:UniProtKB.
DR   GO; GO:0030027; C:lamellipodium; IEA:UniProtKB-SubCell.
DR   GO; GO:0035748; C:myelin sheath abaxonal region; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IBA:GO_Central.
DR   GO; GO:0098793; C:presynapse; IEA:UniProtKB-SubCell.
DR   GO; GO:0034750; C:Scrib-APC-beta-catenin complex; IDA:BHF-UCL.
DR   GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL.
DR   GO; GO:0035591; F:signaling adaptor activity; IDA:UniProt.
DR   GO; GO:0090630; P:activation of GTPase activity; IMP:UniProtKB.
DR   GO; GO:0060561; P:apoptotic process involved in morphogenesis; IMP:UniProtKB.
DR   GO; GO:0043615; P:astrocyte cell migration; IEA:Ensembl.
DR   GO; GO:0060088; P:auditory receptor cell stereocilium organization; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IMP:UniProtKB.
DR   GO; GO:0008283; P:cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0098609; P:cell-cell adhesion; IGI:UniProtKB.
DR   GO; GO:0021747; P:cochlear nucleus development; IEA:Ensembl.
DR   GO; GO:0035089; P:establishment of apical/basal cell polarity; IMP:UniProtKB.
DR   GO; GO:0001768; P:establishment of T cell polarity; ISS:UniProtKB.
DR   GO; GO:0045197; P:establishment or maintenance of epithelial cell apical/basal polarity; NAS:ComplexPortal.
DR   GO; GO:0060603; P:mammary gland duct morphogenesis; ISS:UniProtKB.
DR   GO; GO:0046007; P:negative regulation of activated T cell proliferation; ISS:UniProtKB.
DR   GO; GO:0045930; P:negative regulation of mitotic cell cycle; IDA:UniProtKB.
DR   GO; GO:0001843; P:neural tube closure; IMP:UniProtKB.
DR   GO; GO:0098968; P:neurotransmitter receptor transport postsynaptic membrane to endosome; IBA:GO_Central.
DR   GO; GO:0098887; P:neurotransmitter receptor transport, endosome to postsynaptic membrane; IBA:GO_Central.
DR   GO; GO:0030859; P:polarized epithelial cell differentiation; IMP:UniProtKB.
DR   GO; GO:0050918; P:positive chemotaxis; IMP:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0001921; P:positive regulation of receptor recycling; IMP:UniProtKB.
DR   GO; GO:0032729; P:positive regulation of type II interferon production; ISS:UniProtKB.
DR   GO; GO:0036342; P:post-anal tail morphogenesis; IEA:Ensembl.
DR   GO; GO:0071896; P:protein localization to adherens junction; IMP:BHF-UCL.
DR   GO; GO:0099149; P:regulation of postsynaptic neurotransmitter receptor internalization; IEA:Ensembl.
DR   GO; GO:0048488; P:synaptic vesicle endocytosis; IEA:Ensembl.
DR   GO; GO:0016080; P:synaptic vesicle targeting; IEA:Ensembl.
DR   GO; GO:0042060; P:wound healing; IEA:Ensembl.
DR   CDD; cd00992; PDZ_signaling; 4.
DR   Gene3D; 2.30.42.10; -; 4.
DR   Gene3D; 3.80.10.10; Ribonuclease Inhibitor; 4.
DR   InterPro; IPR001611; Leu-rich_rpt.
DR   InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR   InterPro; IPR032675; LRR_dom_sf.
DR   InterPro; IPR001478; PDZ.
DR   InterPro; IPR036034; PDZ_sf.
DR   PANTHER; PTHR23119; DISCS LARGE; 1.
DR   PANTHER; PTHR23119:SF57; PROTEIN SCRIBBLE HOMOLOG; 1.
DR   Pfam; PF13855; LRR_8; 2.
DR   Pfam; PF00595; PDZ; 4.
DR   SMART; SM00364; LRR_BAC; 10.
DR   SMART; SM00369; LRR_TYP; 11.
DR   SMART; SM00228; PDZ; 4.
DR   SUPFAM; SSF52058; L domain-like; 2.
DR   SUPFAM; SSF50156; PDZ domain-like; 4.
DR   PROSITE; PS51450; LRR; 13.
DR   PROSITE; PS50106; PDZ; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell junction; Cell membrane;
KW   Cell projection; Coiled coil; Cytoplasm; Developmental protein;
KW   Differentiation; Disease variant; Host-virus interaction;
KW   Inhibition of host innate immune response by virus;
KW   Inhibition of host interferon signaling pathway by virus;
KW   Inhibition of host STAT1 by virus; Inhibition of host STAT2 by virus;
KW   Leucine-rich repeat; Lipoprotein; Membrane; Palmitate; Phosphoprotein;
KW   Reference proteome; Repeat; Synapse; Ubl conjugation; Viral immunoevasion.
FT   CHAIN           1..1630
FT                   /note="Protein scribble homolog"
FT                   /id="PRO_0000188303"
FT   REPEAT          37..58
FT                   /note="LRR 1"
FT   REPEAT          60..81
FT                   /note="LRR 2"
FT   REPEAT          83..104
FT                   /note="LRR 3"
FT   REPEAT          106..127
FT                   /note="LRR 4"
FT   REPEAT          129..150
FT                   /note="LRR 5"
FT   REPEAT          152..174
FT                   /note="LRR 6"
FT   REPEAT          175..197
FT                   /note="LRR 7"
FT   REPEAT          198..219
FT                   /note="LRR 8"
FT   REPEAT          221..243
FT                   /note="LRR 9"
FT   REPEAT          244..265
FT                   /note="LRR 10"
FT   REPEAT          267..288
FT                   /note="LRR 11"
FT   REPEAT          290..312
FT                   /note="LRR 12"
FT   REPEAT          313..334
FT                   /note="LRR 13"
FT   REPEAT          336..357
FT                   /note="LRR 14"
FT   REPEAT          359..381
FT                   /note="LRR 15"
FT   REPEAT          382..402
FT                   /note="LRR 16"
FT   DOMAIN          728..815
FT                   /note="PDZ 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          862..950
FT                   /note="PDZ 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          1004..1093
FT                   /note="PDZ 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   DOMAIN          1100..1194
FT                   /note="PDZ 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00143"
FT   REGION          1..818
FT                   /note="Sufficient for targeting to adherens junction and to
FT                   inhibit cell proliferation"
FT   REGION          417..440
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          459..606
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          628..702
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          717..1229
FT                   /note="Interaction with ARHGEF7"
FT                   /evidence="ECO:0000269|PubMed:15182672"
FT   REGION          827..853
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1105..1117
FT                   /note="Interaction with tick-borne encephalitis virus RNA-
FT                   directed RNA polymerase NS5"
FT                   /evidence="ECO:0000269|PubMed:18042258"
FT   REGION          1227..1246
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1277..1489
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1520..1630
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          458..474
FT                   /evidence="ECO:0000255"
FT   COILED          656..701
FT                   /evidence="ECO:0000255"
FT   COILED          1379..1419
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        423..440
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        460..492
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        520..534
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        565..588
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        664..692
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1333..1347
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1380..1402
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1439..1453
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         37
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         378
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         475
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         504
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         688
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         689
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         708
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         764
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         826
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231"
FT   MOD_RES         835
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         853
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         875
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         939
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         1140
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1220
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:15144186,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1223
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1226
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1232
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1276
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1279
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1295
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1298
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1306
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1309
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1342
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231"
FT   MOD_RES         1348
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1378
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1437
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         1445
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1448
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1475
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1486
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         1508
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         1541
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1545
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:24275569"
FT   MOD_RES         1547
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:19690332"
FT   MOD_RES         1561
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1566
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18220336,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   VAR_SEQ         1..81
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_010906"
FT   VAR_SEQ         1565
FT                   /note="L -> LPLSGKKFDYRAFAALPSSRPVYDIQ (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_010908"
FT   VARIANT         422
FT                   /note="P -> L (in dbSNP:rs6558394)"
FT                   /evidence="ECO:0000269|PubMed:15649318,
FT                   ECO:0000269|PubMed:15806148, ECO:0000269|PubMed:8590280,
FT                   ECO:0000269|Ref.3"
FT                   /id="VAR_019429"
FT   VARIANT         454
FT                   /note="P -> S (in NTD; protein interactions not affected by
FT                   the mutation; shows reduced protein localization to the
FT                   cell membrane; dbSNP:rs1302482009)"
FT                   /evidence="ECO:0000269|PubMed:22095531"
FT                   /id="VAR_067219"
FT   VARIANT         1535
FT                   /note="R -> Q (in NTD; protein interactions not affected by
FT                   the mutation; shows reduced protein localization to the
FT                   cell membrane; dbSNP:rs782428100)"
FT                   /evidence="ECO:0000269|PubMed:22095531"
FT                   /id="VAR_067220"
FT   MUTAGEN         4
FT                   /note="C->S: Loss of palmitoylation. Loss of
FT                   palmitoylation, localization to cell-cell junctions and
FT                   function in epithelial cell polarization and signaling
FT                   pathways regulation; when associated with S-10."
FT                   /evidence="ECO:0000269|PubMed:27380321"
FT   MUTAGEN         10
FT                   /note="C->S: Loss of palmitoylation. Loss of
FT                   palmitoylation, localization to cell-cell junctions and
FT                   function in epithelial cell polarization and signaling
FT                   pathways regulation; when associated with S-4."
FT                   /evidence="ECO:0000269|PubMed:27380321"
FT   MUTAGEN         22
FT                   /note="C->S: No effect on palmitoylation."
FT                   /evidence="ECO:0000269|PubMed:27380321"
FT   MUTAGEN         305
FT                   /note="P->L: Decreased palmitoylation. Loss of localization
FT                   at the plasma membrane. Loss of targeting to cell-cell
FT                   junctions. Alters interaction with TJP2. Loss of
FT                   pro-apoptotic function. Loss of function in epithelial cell
FT                   polarization and signaling pathways regulation."
FT                   /evidence="ECO:0000269|PubMed:15182672,
FT                   ECO:0000269|PubMed:15806148, ECO:0000269|PubMed:19041750,
FT                   ECO:0000269|PubMed:27380321"
FT   MUTAGEN         738..739
FT                   /note="LG->AE: Alters interaction with LPP."
FT                   /evidence="ECO:0000269|PubMed:15649318"
FT   MUTAGEN         738
FT                   /note="L->R: Loss of anti-proliferative activity."
FT   MUTAGEN         872..873
FT                   /note="LG->AE: Alters interaction with LPP."
FT                   /evidence="ECO:0000269|PubMed:15649318"
FT   MUTAGEN         1014..1015
FT                   /note="LG->AE: Loss of interaction with LPP and TRIP6."
FT                   /evidence="ECO:0000269|PubMed:15649318"
FT   MUTAGEN         1111..1112
FT                   /note="LG->AE: Alters interaction with LPP."
FT                   /evidence="ECO:0000269|PubMed:15649318"
FT   CONFLICT        1489
FT                   /note="E -> K (in Ref. 2; AAL38976)"
FT                   /evidence="ECO:0000305"
FT   STRAND          725..732
FT                   /evidence="ECO:0007829|PDB:6MYE"
FT   STRAND          734..736
FT                   /evidence="ECO:0007829|PDB:7QS9"
FT   STRAND          740..744
FT                   /evidence="ECO:0007829|PDB:6MYE"
FT   STRAND          751..754
FT                   /evidence="ECO:0007829|PDB:5VWC"
FT   STRAND          757..763
FT                   /evidence="ECO:0007829|PDB:6MYE"
FT   STRAND          765..767
FT                   /evidence="ECO:0007829|PDB:7QTP"
FT   HELIX           768..772
FT                   /evidence="ECO:0007829|PDB:6MYE"
FT   STRAND          779..783
FT                   /evidence="ECO:0007829|PDB:6MYE"
FT   HELIX           793..801
FT                   /evidence="ECO:0007829|PDB:6MYE"
FT   STRAND          805..814
FT                   /evidence="ECO:0007829|PDB:6MYE"
FT   STRAND          815..818
FT                   /evidence="ECO:0007829|PDB:6ESP"
FT   HELIX           820..823
FT                   /evidence="ECO:0007829|PDB:6ESP"
FT   STRAND          860..866
FT                   /evidence="ECO:0007829|PDB:7JO7"
FT   STRAND          875..877
FT                   /evidence="ECO:0007829|PDB:7JO7"
FT   STRAND          893..896
FT                   /evidence="ECO:0007829|PDB:7JO7"
FT   HELIX           902..905
FT                   /evidence="ECO:0007829|PDB:7JO7"
FT   STRAND          914..918
FT                   /evidence="ECO:0007829|PDB:7JO7"
FT   HELIX           928..936
FT                   /evidence="ECO:0007829|PDB:7JO7"
FT   STRAND          940..947
FT                   /evidence="ECO:0007829|PDB:7JO7"
FT   STRAND          997..1000
FT                   /evidence="ECO:0007829|PDB:4WYU"
FT   STRAND          1002..1008
FT                   /evidence="ECO:0007829|PDB:5VWI"
FT   STRAND          1010..1012
FT                   /evidence="ECO:0007829|PDB:4WYU"
FT   STRAND          1016..1020
FT                   /evidence="ECO:0007829|PDB:5VWI"
FT   STRAND          1022..1024
FT                   /evidence="ECO:0007829|PDB:4WYT"
FT   TURN            1027..1030
FT                   /evidence="ECO:0007829|PDB:4WYU"
FT   STRAND          1031..1033
FT                   /evidence="ECO:0007829|PDB:4WYU"
FT   STRAND          1036..1041
FT                   /evidence="ECO:0007829|PDB:5VWI"
FT   HELIX           1046..1049
FT                   /evidence="ECO:0007829|PDB:5VWI"
FT   STRAND          1057..1061
FT                   /evidence="ECO:0007829|PDB:5VWI"
FT   HELIX           1071..1078
FT                   /evidence="ECO:0007829|PDB:5VWI"
FT   STRAND          1080..1090
FT                   /evidence="ECO:0007829|PDB:5VWI"
FT   STRAND          1099..1104
FT                   /evidence="ECO:0007829|PDB:6EEY"
FT   STRAND          1113..1117
FT                   /evidence="ECO:0007829|PDB:6EEY"
FT   STRAND          1119..1122
FT                   /evidence="ECO:0007829|PDB:1UJU"
FT   STRAND          1126..1128
FT                   /evidence="ECO:0007829|PDB:4WYT"
FT   HELIX           1129..1131
FT                   /evidence="ECO:0007829|PDB:6EEY"
FT   STRAND          1134..1139
FT                   /evidence="ECO:0007829|PDB:6EEY"
FT   STRAND          1141..1143
FT                   /evidence="ECO:0007829|PDB:4WYT"
FT   HELIX           1144..1148
FT                   /evidence="ECO:0007829|PDB:6EEY"
FT   STRAND          1156..1160
FT                   /evidence="ECO:0007829|PDB:6EEY"
FT   HELIX           1170..1177
FT                   /evidence="ECO:0007829|PDB:6EEY"
FT   STRAND          1181..1189
FT                   /evidence="ECO:0007829|PDB:6EEY"
SQ   SEQUENCE   1630 AA;  174915 MW;  9CF28E3510E8BDB4 CRC64;
     MLKCIPLWRC NRHVESVDKR HCSLQAVPEE IYRYSRSLEE LLLDANQLRE LPKPFFRLLN
     LRKLGLSDNE IQRLPPEVAN FMQLVELDVS RNDIPEIPES IKFCKALEIA DFSGNPLSRL
     PDGFTQLRSL AHLALNDVSL QALPGDVGNL ANLVTLELRE NLLKSLPASL SFLVKLEQLD
     LGGNDLEVLP DTLGALPNLR ELWLDRNQLS ALPPELGNLR RLVCLDVSEN RLEELPAELG
     GLVLLTDLLL SQNLLRRLPD GIGQLKQLSI LKVDQNRLCE VTEAIGDCEN LSELILTENL
     LMALPRSLGK LTKLTNLNVD RNHLEALPPE IGGCVALSVL SLRDNRLAVL PPELAHTTEL
     HVLDVAGNRL QSLPFALTHL NLKALWLAEN QAQPMLRFQT EDDARTGEKV LTCYLLPQQP
     PPSLEDAGQQ GSLSETWSDA PPSRVSVIQF LEAPIGDEDA EEAAAEKRGL QRRATPHPSE
     LKVMKRSIEG RRSEACPCQP DSGSPLPAEE EKRLSAESGL SEDSRPSAST VSEAEPEGPS
     AEAQGGSQQE ATTAGGEEDA EEDYQEPTVH FAEDALLPGD DREIEEGQPE APWTLPGGRQ
     RLIRKDTPHY KKHFKISKLP QPEAVVALLQ GMQPDGEGPV APGGWHNGPH APWAPRAQKE
     EEEEEEGSPQ EEEEEEEEEN RAEEEEASTE EEDKEGAVVS APSVKGVSFD QANNLLIEPA
     RIEEEELTLT ILRQTGGLGI SIAGGKGSTP YKGDDEGIFI SRVSEEGPAA RAGVRVGDKL
     LEVNGVALQG AEHHEAVEAL RGAGTAVQMR VWRERMVEPE NAVTITPLRP EDDYSPRERR
     GGGLRLPLLP PESPGPLRQR HVACLARSER GLGFSIAGGK GSTPYRAGDA GIFVSRIAEG
     GAAHRAGTLQ VGDRVLSING VDVTEARHDH AVSLLTAASP TIALLLEREA GGPLPPSPLP
     HSSPPTAAVA TTSITTATPG VPGLPSLAPS LLAAALEGPY PVEEIRLPRA GGPLGLSIVG
     GSDHSSHPFG VQEPGVFISK VLPRGLAARS GLRVGDRILA VNGQDVRDAT HQEAVSALLR
     PCLELSLLVR RDPAPPGLRE LCIQKAPGER LGISIRGGAR GHAGNPRDPT DEGIFISKVS
     PTGAAGRDGR LRVGLRLLEV NQQSLLGLTH GEAVQLLRSV GDTLTVLVCD GFEASTDAAL
     EVSPGVIANP FAAGIGHRNS LESISSIDRE LSPEGPGKEK ELPGQTLHWG PEATEAAGRG
     LQPLKLDYRA LAAVPSAGSV QRVPSGAAGG KMAESPCSPS GQQPPSPPSP DELPANVKQA
     YRAFAAVPTS HPPEDAPAQP PTPGPAASPE QLSFRERQKY FELEVRVPQA EGPPKRVSLV
     GADDLRKMQE EEARKLQQKR AQMLREAAEA GAEARLALDG ETLGEEEQED EQPPWASPSP
     TSRQSPASPP PLGGGAPVRT AKAERRHQER LRVQSPEPPA PERALSPAEL RALEAEKRAL
     WRAARMKSLE QDALRAQMVL SRSQEGRGTR GPLERLAEAP SPAPTPSPTP VEDLGPQTST
     SPGRLSPDFA EELRSLEPSP SPGPQEEDGE VALVLLGRPS PGAVGPEDVA LCSSRRPVRP
     GRRGLGPVPS
//
